MOREPEN LABORATORIES LTD.

Morepen Laboratories Ltd has announced its 41st Annual General Meeting (AGM) scheduled for September 26, 2026, to be held via video conferencing. The company has dispatched letters to members without registered email IDs, providing access to the Annual Report for FY 2025-26 through a weblink, QR code, and specified path. The AGM will include electronic voting for resolutions. Additionally, the Board of Directors has proposed a final dividend of ₹0.20 per equity share for FY 2025-26, subject to member approval. Members are reminded to submit requisite tax exemption forms by September 23, 2026, and ensure their KYC is updated for dividend credit, as physical dividend warrants have been discontinued.

Morepen Laboratories Ltd has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, which is an integral part of the Annual Report, details the company's corporate identity, business activities, operations, and employee data. Key business segments include API manufacturing (56.33% turnover) and Medical Devices (35.60%). The company serves over 80 countries, with exports contributing 40% of its total turnover. The BRSR is filed as per SEBI regulations and is available on the company's website.

Morepen Laboratories Ltd has announced its 41st Annual General Meeting (AGM) will be held on Saturday, September 26, 2026, at 1:00 p.m. IST, conducted via Video Conferencing/Other Audio Video Means (VC/OAVM). The meeting will cover ordinary business such as adopting financial statements for FY2025-26 and declaring a final dividend of ₹0.20 per equity share. Special business includes ratifying the remuneration of cost auditors and approving the elevation of Mr. Sanjay Suri from Whole-Time Director to Managing Director. The cut-off date for voting eligibility and the record date for the dividend is September 19, 2026, with remote e-voting commencing on September 23 and ending on September 25, 2026.

Morepen Laboratories Ltd has filed its Annual Report for the financial year 2025-26, along with the notice for its 41st Annual General Meeting (AGM). The AGM is scheduled for September 26, 2026, and will be conducted via Video Conferencing/Other Audio Video Means. The report highlights the company's strategic focus on strengthening its people, technologies, processes, and purpose, serving millions through APIs, formulations, OTC healthcare products, and home diagnostics. It also mentions investments in manufacturing capacity, innovation-led chemistry, digital health, and global partnerships. The company secured a significant multi-year CDMO mandate valued at approximately ₹825 Crore (USD 91 million) from a leading global pharmaceutical company.

Morepen Laboratories Ltd announced that its wholly-owned subsidiary, Morepen RX Limited (MRX), has allotted 2 crore equity shares of Rs. 10 each at par, aggregating to Rs. 20 crore. This allotment is pursuant to a rights issue by MRX to the parent company. Following this, Morepen Laboratories' shareholding in MRX has increased to 2,70,82,356 equity shares, though MRX continues to remain a wholly-owned subsidiary. The funds are intended to strengthen MRX's capital base and support its business operations in the pharmaceutical sector, specifically in the sales and marketing of Branded Prescription ('Rx') products.

Morepen Laboratories Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, concerning the utilization of proceeds from its Qualified Institutions Placement (QIP) issue. The report, issued by CARE Ratings Limited, confirms that the utilization of funds is in line with the objects disclosed in the offer document, with no deviations reported. The QIP issue aggregated to Rs. 200.00 crore. The filing adheres to SEBI regulations, specifically Regulation 32 of LODR and Regulation 173A of ICDR.

Morepen Laboratories Ltd announced its 41st Annual General Meeting (AGM) will be held on September 26, 2026. The Board of Directors, in a meeting on August 4, 2026, approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. A record date of September 19, 2026, was set for determining eligibility for the final dividend for FY26, subject to member approval at the AGM. The company also seeks member approval for extending the timeline to hive off its Medical Devices Business into a subsidiary and for the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for three years from October 20, 2026.

Morepen Laboratories Ltd announced the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a further period of three years, effective from October 20, 2026, to October 19, 2029. This decision is subject to shareholder approval at the upcoming 41st Annual General Meeting (AGM). The Board also approved un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, and set a record date for final dividend determination. Additionally, the company is seeking member approval for extending the timeline to hive off its Medical Devices Business into a subsidiary.

Morepen Laboratories Ltd's Board of Directors met on August 4, 2026, to approve the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also set Saturday, September 19, 2026, as the record date for determining eligibility for the final dividend for the financial year ended March 31, 2026, subject to member approval at the upcoming 41st AGM. Additionally, the board approved the extension of the timeline for hiving off the Medical Devices Business into its subsidiary, Morepen Medipath Limited, and the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a further three-year term.

Morepen Laboratories Ltd. announced its highest-ever quarterly revenue and earnings for Q1 FY27, with revenue reaching ₹575.31 Cr, a 34% year-on-year increase. EBITDA surged by 207% to ₹87.72 Cr, and Profit After Tax (PAT) grew by 394% to ₹56.35 Cr. The company's CDMO mandate, valued at ₹825 Cr, entered full-scale commercialization, with ₹58 Cr in dispatches completed during the quarter. API business grew 31% with exports up 42%, and Medical Devices saw 19% growth. The company also maintained a strong regulatory record with four consecutive USFDA inspections yielding Nil Form 483 observations.